Form 4 for CVKD Cadrenal Therapeutics, Inc.
Accepted 2023-01-24 00:00:00 ET · period of report 2023-01-24 · accession 0001213900-23-004886 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-24 | 2023-01-24 | CVKD | WILSON GLYNN | Dir | C - Cnv Deriv | — | +50.0K | 50.0K | New | — |
| D | 2023-01-24 | 2023-01-24 | CVKD | WILSON GLYNN | Dir | C - Cnv Deriv | — | -50.0K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-24 | C | A | 50,000 | — | 50,000 | D | — | — | (F1) Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. |
| 2 | Derivative | Convertible Promissory Note | 2023-01-24 | C | D | 50,000 | — | 0 | D | $1.00 · — to — | 50,000 Common Stock | (F1) Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. |